Showing 1 - 7 results of 7 for search 'Daniel S. Talmor', query time: 0.03s Refine Results
  1. 1
    Trends in severity of illness on ICU admission and mortality among the elderly.

    Trends in severity of illness on ICU admission and mortality among the elderly. by Lior Fuchs, Victor Novack, Stuart McLennan, Leo Anthony Celi, Yael Baumfeld, Shinhyuk Park, Michael D Howell, Daniel S Talmor

    Published 2014-01-01
    Get full text
    Article
  2. 2
    Predicting mortality in adults with suspected infection in a Rwandan hospital: an evaluation of the adapted MEWS, qSOFA and UVA scores

    Predicting mortality in adults with suspected infection in a Rwandan hospital: an evaluation of the adapted MEWS, qSOFA and UVA scores by Jennifer Rickard, Amanda Klinger, Ariel Mueller, Tori Sutherland, Christophe Mpirimbanyi, Elie Nziyomaze, Jean-Paul Niyomugabo, Zack Niyonsenga, Daniel S Talmor, Elisabeth Riviello

    Published 2021-02-01
    Get full text
    Article
  3. 3
    Examining the Role of Race in End-of-Life Care in the Intensive Care Unit: A Single-Center Observational Study

    Examining the Role of Race in End-of-Life Care in the Intensive Care Unit: A Single-Center Observational Study by Shahla Siddiqui, Diana Bouhassira, Lauren Kelly, Margaret Hayes, Austin Herbst, Sarah Ohnigian, Luke Hedrick, Kimberly Ona Ayala, Daniel S. Talmor, Jennifer P. Stevens

    Published 2023-09-01
    Get full text
    Article
  4. 4
    Predicting Mortality in Low-Income Country ICUs: The Rwanda Mortality Probability Model (R-MPM).

    Predicting Mortality in Low-Income Country ICUs: The Rwanda Mortality Probability Model (R-MPM). by Elisabeth D Riviello, Willy Kiviri, Robert A Fowler, Ariel Mueller, Victor Novack, Valerie M Banner-Goodspeed, Julia L Weinkauf, Daniel S Talmor, Theogene Twagirumugabe

    Published 2016-01-01
    Get full text
    Article
  5. 5
    Study of alteplase for respiratory failure in severe acute respiratory syndrome coronavirus 2/COVID‐19: Study design of the phase IIa STARS trial

    Study of alteplase for respiratory failure in severe acute respiratory syndrome coronavirus 2/COVID‐19: Study design of the phase IIa STARS trial by Hunter B. Moore, Christopher D. Barrett, Ernest E. Moore, Rashi Jhunjhunwala, Robert C. McIntyre, Peter K Moore, Janice Wang, Negin Hajizadeh, Daniel S. Talmor, Angela Sauaia, Michael B. Yaffe

    Published 2020-08-01
    Get full text
    Article
  6. 6
    Fibrinolytic therapy for refractory COVID‐19 acute respiratory distress syndrome: Scientific rationale and review

    Fibrinolytic therapy for refractory COVID‐19 acute respiratory distress syndrome: Scientific rationale and review by Christopher D. Barrett, Hunter B. Moore, Ernest E. Moore, Robert C. McIntyre, Peter K. Moore, John Burke, Fei Hua, Joshua Apgar, Daniel S. Talmor, Angela Sauaia, Deborah R. Liptzin, Livia A. Veress, Michael B. Yaffe

    Published 2020-05-01
    Get full text
    Article
  7. 7
    MUlticenter STudy of tissue plasminogen activator (alteplase) use in COVID‐19 severe respiratory failure (MUST COVID): A retrospective cohort study

    MUlticenter STudy of tissue plasminogen activator (alteplase) use in COVID‐19 severe respiratory failure (MUST COVID): A retrospective cohort study by Christopher D. Barrett, Hunter B. Moore, Ernest E. Moore, Dudley Benjamin Christie III, Sarah Orfanos, Lorenzo Anez‐Bustillos, Rashi Jhunjhunwala, Sabiha Hussain, Shahzad Shaefi, Janice Wang, Negin Hajizadeh, Elias N. Baedorf‐Kassis, Ammar Al‐Shammaa, Krystal Capers, Valerie Banner‐Goodspeed, Franklin L. Wright, Todd Bull, Peter K. Moore, Hannah Nemec, John Thomas Buchanan, Cory Nonnemacher, Natalie Rajcooar, Ramona Ramdeo, Mena Yacoub, Ana Guevara, Aileen Espinal, Laith Hattar, Andrew Moraco, Robert McIntyre, Daniel S. Talmor, Angela Sauaia, Michael B. Yaffe

    Published 2022-02-01
    Get full text
    Article

Search Tools: